PFE · News · 20261112N

GLP-1 Market Competition

PFIZER INC · 2026-11-12 · Importance 20 · Surprise 24

Eli Lilly’s orforglipron received approval in China, placing it in competition with Novo Nordisk’s and Pfizer’s once-weekly GLP-1 injections and Innovent Biologics’ product. Lilly and Novo expect oral weight-loss drugs to attract patients reluctant to use injections. China’s National Health Commission has projected that more than 65% of the population could be overweight or obese by 2030.

Key facts